The earnings call presented a mixed picture with significant growth in key products like Crysvita and Poteligeo, and promising R&D advancements, but faced challenges with decreased revenue and profits, notably due to restructuring impacts in Japan and APAC. The sentiment is balanced with notable achievements and ongoing challenges.

Company Guidance -

Q3 2025

In the Q2 financial results presentation for the fiscal year ending December 31, 2025, Kyowa Kirin Co., Ltd. provided detailed guidance on several key performance metrics. The company reported a revenue of JPY230.7 billion, a 1% decrease compared to the same period last year, attributed to business restructuring in the APAC region and NHI price reductions in Japan. Core operating profit fell by 21% to JPY35 billion, primarily due to a decline in gross profit and a 7% increase in R&D expenses. Interim profit decreased by 57% to JPY16.3 billion, impacted by JPY9.4 billion in extra retirement payments from a voluntary retirement program in Japan. Despite these challenges, Crysvita and Poteligeo showed strong growth in North America and EMEA, with Crysvita achieving a 10% YoY increase. The company projected that revenue and gross profit, currently at 48% of the full-year forecast, would align with expectations as they typically rise in the latter half of the fiscal year. Core operating profit was at 44% of the annual plan, while interim profit progress was at 29%. The company remains committed to achieving its full-year targets, aided by strategic sales growth and operational efficiencies, including AI-driven promotional activities.

Crysvita Sales Growth

Crysvita global sales for H1 increased 10% YoY to JPY99.8 billion, with strong performance in North America and EMEA, supported by increased treatment among adult patients and promotional activities.

Poteligeo Revenue Increase

Global revenue for Poteligeo reached JPY21.6 billion, a 14% increase YoY, with successful promotional strategies using AI and strong growth in North America and Europe.

Successful R&D and Pipeline Progress

Ziftomenib has shown promising results in trials, with a favorable safety profile and efficacy, and has been submitted for FDA approval. Rocatinlimab shows potential for unique treatment value and is progressing well in trials.

Kyowa Kirin Co (JP:4151) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JP:4151 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 31, 2025	2025 (Q3)	31.06 / -	34.44	―	―	―
Jul 31, 2025	2025 (Q2)	31.84 / 19.40	43.5	-55.40% (-24.10)
May 01, 2025	2025 (Q1)	26.11 / 11.78	27.26	-56.79% (-15.48)		―
Feb 06, 2025	2024 (Q4)	23.90 / 7.86	51.41	-84.71% (-43.55)		―
Oct 31, 2024	2024 (Q3)	35.39 / 34.44	59.35	-41.97% (-24.91)		―
Aug 01, 2024	2024 (Q2)	28.47 / 43.50	16.53	163.16% (+26.97)		―
May 07, 2024	2024 (Q1)	28.50 / 27.26	23.74	14.83% (+3.52)		―
Feb 07, 2024	2023 (Q4)	53.93 / 51.41	8.11	533.91% (+43.30)		―
Nov 01, 2023	2023 (Q3)	61.25 / 59.35	26.41	124.73% (+32.94)		―
Aug 03, 2023	2023 (Q2)	26.07 / 16.53	35.31	-53.19% (-18.78)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JP:4151 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	¥2565.50	¥2597.00	+1.23%
May 01, 2025	¥2198.03	¥2211.36	+0.61%
Feb 06, 2025	¥2226.67	¥2212.84	-0.62%
Oct 31, 2024	¥2449.95	¥2462.15	+0.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kyowa Kirin Co (JP:4151) report earnings?

Kyowa Kirin Co (JP:4151) is schdueled to report earning on Oct 31, 2025, TBA (Confirmed).

What is Kyowa Kirin Co (JP:4151) earnings time?

Kyowa Kirin Co (JP:4151) earnings time is at Oct 31, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Kyowa Kirin Co stock?

The P/E ratio of Kyowa Kirin Co is N/A.

What is JP:4151 EPS forecast?

JP:4151 EPS forecast for the fiscal quarter 2025 (Q3) is 31.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing